In the ever-evolving landscape of pharmaceutical research and development, the precise selection of chemical intermediates is paramount to successful drug synthesis. Among these critical components, 2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one, identified by its CAS number 20348-21-4, stands out as a highly valuable pharmaceutical intermediate. Its unique chemical structure and consistent purity make it an indispensable building block for creating advanced Active Pharmaceutical Ingredients (APIs).

The compound, often appearing as a white powder, possesses a molecular formula of C9H10N2O2 and a molecular weight of approximately 178.18800. Its physical and chemical properties, such as a density of 1.176 g/cm³ and a high boiling point of 352.5°C, indicate a stable and reliable compound suitable for various chemical reactions. The assay purity, typically exceeding 98.0%, is a testament to the rigorous manufacturing standards employed by leading suppliers, ensuring that even trace impurities do not compromise the integrity of the final pharmaceutical product.

The primary application of 2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one lies in its role as a chemical building block for synthesizing complex molecules. Pharmaceutical chemists utilize its structural framework to construct novel therapeutic agents, potentially targeting a range of medical conditions. Its versatility in drug synthesis makes it a sought-after component in the early stages of drug discovery and later in the scale-up process for commercial production. For companies looking to buy 2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one, sourcing from a reliable manufacturer in China, like NINGBO INNO PHARMCHEM CO.,LTD., offers the advantage of accessing high-quality materials coupled with competitive pricing and efficient supply chains.

The importance of this compound in drug development cannot be overstated. It serves as a crucial link in multi-step synthesis pathways, where the quality and availability of intermediates directly impact the efficiency and cost-effectiveness of producing life-saving medications. By partnering with experienced manufacturers who understand the stringent requirements of the pharmaceutical industry, companies can ensure a steady supply of this essential pharmaceutical intermediate, thereby accelerating their research and development timelines and ultimately bringing vital treatments to market.